Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betablocker Withdrawal in HFpEF with Chronotropic Incompetence
2017-005077-39Phase 4Completed
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of propranolol in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by INCLIVA Biomedical Research Institute. Primary endpoints: Peak oxygen consumption at 15 and 30 days and Heart rate at 15 and 30 days. Started May 2018; status: completed.
02
Drugs
propranolol
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2017-005077-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005077-39.